YARD-FORCE
28.6.2024 06:01:33 CEST | Business Wire | Press release
Yard Force is proud to unveil the 100W Portable Solar Panel LX SPP10, a highly efficient and versatile solar charger designed to provide optimal power supply in conjunction with Yard Force Power Stations. Perfect for outdoor activities and emergency power needs, the LX SPP10 ensures reliable and eco-friendly energy wherever you go. The Yard Force 100W Portable Solar Panel is now available for purchase on Amazon.de here.
Key Features of the Yard Force 100W Portable Solar Panel LX SPP10:
- Mobile Power Supply: Specifically designed to maximize performance when paired with Yard Force Power Stations, the 100W solar panel boasts an impressive efficiency rate of 23.5% and 95% transparency for efficient conversion of solar energy into electrical power.
- Waterproof Design: With its seamless construction, the Yard Force 100W Solar Panel is waterproof, making it perfect for all outdoor activities. Whether camping, hiking, or in an emergency situation, this solar panel ensures a continuous power supply in any weather.
- Protection and Flexibility: The included carrying case with a handle protects the solar panel during transport. Adjustable stands allow for flexible positioning, and the panel can be connected with additional solar panels for increased power.
- Intelligent Technology: Equipped with various outputs – 1 * 65W PD, 1 * 18W USB-A QC, 1 * 12W USB-A, and 1 * 19.5V DC5521 – the Yard Force 100W Solar Panel is compatible with Yard Force Power Stations. It includes an intelligent IC chip that recognizes connected devices, maximizes charging speed, and protects against overcharging and overloading.
- Perfect Compatibility: Ideal for use with Yard Force Power Stations LX PS300, LX PS600, and LX PS1200, the 100W solar panel enables autonomous power supply during outdoor activities, ensuring you stay connected and powered up.
Customer Popularity in Germany:
The Yard Force 100W Portable Solar Panel LX SPP10 has quickly gained popularity in the German market for its reliability and efficiency. Available for purchase on Amazon.de, this solar panel continues to receive positive reviews and high demand from satisfied customers.
For more information and to purchase the Yard Force 100W Portable Solar Panel, visit Amazon.de.
About Yard Force:
Yard Force is a global leader in innovative garden tools and outdoor power equipment. Known for our dedication to quality, performance, and customer satisfaction, we strive to enhance the outdoor experience with our cutting-edge products. Yard Force is committed to delivering reliable and efficient solutions that meet the diverse needs of our customers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627811456/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom